In last trading session, Karyopharm Therapeutics Inc (NASDAQ:KPTI) saw 2.26 million shares changing hands with its beta currently measuring 0.09. Company’s recent per share price level of $0.60 trading at -$0.03 or -4.76% at ring of the bell on the day assigns it a market valuation of $75.71M. That closing price of KPTI’s stock is at a discount of -183.33% from its 52-week high price of $1.70 and is indicating a premium of 3.33% from its 52-week low price of $0.58.
For Karyopharm Therapeutics Inc (KPTI), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.57. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.26 in the current quarter.
Karyopharm Therapeutics Inc (NASDAQ:KPTI) trade information
Upright in the red during last session for losing -4.76%, in the last five days KPTI remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $0.60 price level, adding 7.99% to its value on the day. Karyopharm Therapeutics Inc’s shares saw a change of -11.28% in year-to-date performance and have moved 0.32% in past 5-day. Karyopharm Therapeutics Inc (NASDAQ:KPTI) showed a performance of -9.10% in past 30-days.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 88.0% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 14. It follows that stock’s current price would drop -400.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -400.0% for stock’s current value.
Karyopharm Therapeutics Inc (KPTI) estimates and forecasts
This year revenue growth is estimated to rise 3.37% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 35.16M for the same. And 6 analysts are in estimates of company making revenue of 37.62M in the next quarter. Company posted 33.13M and 42.79M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 16.79% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 6.76% while estimates for its earnings growth in next 5 years are of 30.52%.
Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s Major holders
VANGUARD GROUP INC is the top institutional holder at KPTI for having 7.65 million shares of worth $6.64 million. And as of 2024-06-30, it was holding 6.6299 of the company’s outstanding shares.
The second largest institutional holder is EVERSEPT PARTNERS, LP, which was holding about 4.99 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.3196 of outstanding shares, having a total worth of $4.33 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Explorer Fund, Inc. are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 3.42 shares of worth $2.05 million or 2.71% of the total outstanding shares. The later fund manager was in possession of 2.01 shares on Oct 31, 2024 , making its stake of worth around $1.2 million in the company or a holder of 1.59% of company’s stock.
